Clinical Trial Update: G-CSF in the Treatment of Toxic Epidermal Necrolysis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating granulocyte colony-stimulating factor (filgrastim) for toxic epidermal necrolysis and Stevens-Johnson syndrome. The Uni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stevens-johnson Syndrome
• Toxic Epidermal Necrolysis

Drugs mentioned

• Filgrastim (filgrastim)

Snippet

Sponsor: University of Liege | Conditions: Stevens - Johnson Syndrome | Phase 4 | Status: COMPLETED